Publication:
Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Afsar, B.
Afsar, R. E.
Kuwabara, M.
Ortiz, A.
Covic, A.

Publication Date

Language

Type

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Day by day, the health and economical burden of cancer increases globally. Indeed it can be considered that there is ''cancer pandemic''. Blocking the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors (ACEI) or angiotensin-receptor blockers (ARB) are widely used measures to treat hypertension and heart failure. It has been recently suggested the activation and blocking of RAS has been associated with various types of cancer in epidemiological and experimental studies. Various studies have shown that RAS blockage is protective in some cancers. However, although fewer, contradictory data also showed that RAS blockage is either not related or adversely related to cancer. Although the reasons for these findings are not exactly known, different types of receptors and effectors in RAS may account for these findings. In the current review, we summarize the different RAS receptors and cancer development with regard to epidemiology, and pathogenesis including cell signaling pathways, apoptosis, genetic and epigenetic factors.

Source

Publisher

Springer

Subject

Oncology

Citation

Has Part

Source

Clinical and Translational Oncology

Book Series Title

Edition

DOI

10.1007/s12094-020-02488-3

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

1

Views

0

Downloads

View PlumX Details